Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AutoCD6-CAR Tregs in Stage 3 Type 1 Diabetes
NCT07395050Phase 1Not yet recruiting
- Sponsor
- City of Hope
- Start
- Nov 2026
- Primary completion
- Feb 2028
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CD6/CTLA4 CoRe-T in type 1 diabetes mellitus (T1D), sponsored by City of Hope. Primary endpoints: Toxicity, CRS, ICANS, hyperglycemia/DKA at 28 days and Feasibility of investigational product manufacture at 28 days. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
CD6/CTLA4 CoRe-T
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT07395050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07395050.